Find Funding Opportunities

The purpose of this Alzheimers Disease-Related Dementia (ADRD) initiative is to promote the development and distribution of innovative technologies, methods, protocols, and biomedical materials that enhance combined human neuropathology and neuroimaging research with data aimed at understanding the underlying pathophysiology of in vivo imaging results typically associated with vascular contributions to cognitive impairment and dementia (VCID) in TBI-related dementia and other ADRD diagnoses. Resources developed under this FOA must follow open data sharing practices and are intended to expand the broader research communitys capacity to perform research aimed at neuropathologically-informed understanding of the vascular pathophysiology of clinically-relevant, in vivo neuroimaging findings.

This Funding Opportunity Announcement (FOA) solicits applications for team-centric development and validation of innovative non-invasive imaging technologies that could have a transformative impact on the study of brain function/connectivity. Applications are expected to turn a novel concept into a functional prototype using this phased grant mechanism. The feasibility should be established by the end of its first phase and serve as a foundation for the transition to its second phase. Fully developing the technology into a functional prototype and validating it by in-vivo animal or human function/connectivity imaging are anticipated in the second phase. The research plan should provide a realistic timeline and tangible milestones to support the proposed development effort. Awards will be integrated into the BRAIN Non-Invasive Imaging Consortium, as a coordinated network on brain function/connectivity imaging.

The goal of this Notice of Special Interest (NOSI) is to strengthen NIH-funded biomedical data repositories to better enable data discoverability, interoperability, and reuse by aligning with the FAIR and TRUST principles and using metrics to measure their effectiveness. This NOSI provides an opportunity for existing repositories to increase FAIR-ness and TRUST-worthiness to improve their usage, utility, and impact throughout the data resource lifecycle.

The All of Us Research Program (All of Us) within the Office of the Director (OD) encourages investigators to apply for grant applications that will advance research in high-priority mission areas of the Institutes, Centers, and Offices (ICOs) through two companion FOAs (1) one to use standard methods and approaches to analyze currently available data within the All of Us Research Programs Researcher Workbench and (2) one to develop new methods, models, and tools and use them to analyze data in the Researcher Workbench. The new tools will be made broadly available to the scientific community. This FOA uses the R21 grant mechanism for new tool development and application, while the companion FOA (link) uses the R03 grant mechanism to support data analysis using standard methods.

The All of Us Research Program (All of Us) within the Office of the Director (OD) encourages investigators to apply for grant applications that will advance research in high-priority mission areas of the Institutes, Centers, and Offices (ICOs) through two companion FOAs (1) one to use standard methods and approaches to analyze currently available data within the All of Us Research Programs Researcher Workbench and (2) one to develop new methods, models, and tools and use them to analyze data in the Researcher Workbench. The new tools will be made broadly available to the scientific community. This FOA uses the R03 grant mechanism to support data analysis using standard methods, while the companion FOA (link) uses the R21 mechanism for new tool development and application.

The goal of this effort is to support the development and validation of next generation platforms and analytic approaches to precisely quantify behaviors in humans and link them with simultaneously recorded brain activity. Tools used for analyzing behavior should be multi-modal and should be able to be linked to brain activity and thus have the accuracy, specificity, temporal resolution, and flexibility commensurate with tools used to measure and modulate the brain circuits that give rise to those behaviors. This phased award will support novel tool development (i.e., hardware/software) in the R61 phase and synchronization of novel tools for measuring behavior and human brain activity in the R33 phase.

This funding opportunity announcement is designed to support biomedical knowledgebases. Biomedical knowledgebases under this announcement should have the primary function to extract, accumulate, organize, annotate, and link growing bodies of information related to core datasets. Support for data curation should include efficient and effective methods of curation that scale to the needs of community and include semi-automated methods.Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the knowledgebase. Applications that have a significant focus on software and tool development are not appropriate for this activity.

This funding opportunity announcement is designed to support biomedical data repositories. Biomedical data repositories under this announcement should have the primary function to ingest, archive, preserve, manage, distribute, and make accessible the data related to a particular system or systems. Support for data curation must be limited to that which improves the efficiency and accessibility of data ingestion, management, and use and reuse by the user communities.Support for software and tool development must be limited to that which provides essential functions or significantly increases the efficiency of operation of the repository. Applications that have a significant focus on software and tool development are not appropriate for this activity.

The purpose of this funding opportunity announcement (FOA) is to invite applications to participate as the National Data Management Center (NDMC) for the NIH Stroke Trials Network. Established by NINDS in 2013, the goal of the NIH StrokeNet is to harness the leadership and experience of the stroke research field to maximize efficiencies for developing, promoting and conducting high-quality, multi-site clinical trials focused on promising interventions for stroke prevention, treatment, and recovery with the objective of having a balanced portfolio between all three approaches. Multi-site exploratory and confirmatory Phase 3 clinical trials as well as biomarker-validation studies that are immediately preparatory to trials and ancillary studies designed to add scientific aims to active studies will be coordinated through a National Coordinating (NCC) and National Data Management Centers (NDMC) and multiple regional coordinating stroke centers (RCC's) with strong collaborative relationships between vascular neurology, emergency medicine, interventional neuroradiology, neurosurgery, neurointensive care, neuroimaging, stroke rehabilitation, and pediatric neurology. The network will provide a robust, standardized, and accessible infrastructure to provide the development and implementation of protocols in stroke prevention, treatment, and recovery. The NDMC will be responsible for centralizing, harmonizing and coordinating all aspects of data collection for studies conducted in the network. Projects will be developed both from investigators both within the network as well as from investigators or industry partners outside of the network; therefore the data center for the stroke network must be able to efficiently collaborate with all parties. This FOA solicits applications for the National Data Management Center for the Stroke Trials Network. Separate FOAs solicit applications for the Regional Coordinating Stroke Centers and the National Coordinating Center.

This Notice of Special Interest is to advise the research community of NINDS interest in clinical trials to study epidural stimulation in spinal cord injury that meet the requirements of PAR-21-237 NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) Funding Opportunity Announcement.